Vistagen’s positive PhIII for social anxiety nasal spray pushes stock price up 1,000+%

San Fran­cis­co-based Vista­gen saw its stock soar more than 1,000% at one point on Mon­day af­ter un­veil­ing pos­i­tive topline re­sults from a Phase III tri­al show­ing its nasal spray helped adults with so­cial anx­i­ety dis­or­der.

The Phase III PAL­ISADE-2 tri­al of 140 sub­jects met its pri­ma­ry end­point, with the ex­per­i­men­tal drug known as fase­dienol demon­strat­ing a sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence in av­er­age Sub­jec­tive Units of Dis­tress (SUDS) score dur­ing a pub­lic speak­ing chal­lenge, when com­pared to place­bo (p=0.015), the com­pa­ny said. Vista­gen al­so not­ed that the tri­al met its sec­ondary end­point, too, demon­strat­ing a sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence in the pro­por­tion of clin­i­cian-as­sessed re­spon­ders be­tween fase­dienol and place­bo as mea­sured by the CGI-I scale (p=0.033).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.